CORRECTION



Corrections to: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma

Peng Yuan¹ · Jinhua Song² · Fei Wang¹ · Guangyu Zhu³ · Baoan Chen¹

Published online: 13 December 2022 © Springer Science+Business Media, LLC, part of Springer Nature 2022

Correction to: Investigational New Drugs (2022) 40:1125–1132 https://doi.org/10.1007/s10637-022-01257-z

Corrections are needed to the original publication.

1. An article note has been added. Second author Jinhua Song is the co-lead author.

2. Page 1, Abstract section, the 1st sentence under Methods sub-section should read "Enrolled in this retrospective study were patients with unresectable ICC who received TACE-L between June 2019 and December 2020" (January 2015 and May 2018 was changed to June 2019 and December 2020).

3. Page 2, Materials and Methods, second to the last sentence under Patient selection should read "The study was approved by the institutional review board of Zhongda Hospital affiliated to the Southeast University School of Medicine (Nanjing, China) and The First Affiliated Hospital of Nanjing Medical University (Nanjing, China), and carried out in accordance with the Helsinki Declaration (as revised

The online version of the original article can be found at https://doi. org/10.1007/s10637-022-01257-z.

Song Jinhua is the co-lead author.

⊠ Baoan Chen cba8888@hotmail.com

- ¹ Department of Hematology and Oncology (Key Discipline of Jiangsu Medicine), Medical School, Zhongda Hospital, Southeast University, 210009 Nanjing, Jiangsu Province, P.R. China
- ² Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, 210029 Nanjing, Jiangsu Province, P.R. China
- ³ Department of Interventional Radiology, Medical School, Zhongda Hospital, Southeast University, 210009 Nanjing, Jiangsu Province, P.R. China

🖄 Springer

in 2013)" (and The First Affiliated Hospital of Nanjing Medical University (Nanjing, China) has been added.

The authors apologize for corrections and further state that changes to the text does not affect the overall outcome of the study.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.